Research site

Pompano Beach, Florida 33064

1 studies enrolling now · 17 studies all time

What they study most

APOL1-Mediated Kidney Disease, Acute Ischaemic Stroke, Anemia, COVID-19, Intracerebral Hemorrhage, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Non-Dialysis-Dependent Chronic Kidney Disease, Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Schizoaffective Disorder

Studies at this site

• Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease — Recruiting now
• Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. — Completed
• Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults — Completed
• Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults — Completed
• Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease — Completed
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) — Completed
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 — Stopped early
• A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD — Completed
• [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] — Completed
• Natalizumab Re-Initiation of Dosing — Completed
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis — Completed
• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) — Stopped early
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis — Completed
• Treatment Interruption of Natalizumab — Completed
• A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder — Completed
• Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke — Completed